NYR Nyrada Inc.
Healthcare · Biotechnology
· website
$0.69
52wk 0.23 – 1.44
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Nyrada Inc.
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$169.26M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.93
EV / EBITDA
-26.15
Price / Book
17.12
ROE
-71.0%
Operating margin
-415.6%
Net margin
-234.3%
Total cash
$7.12M
Total debt
$0
Current ratio
19.00
Debt / Equity
—
Free cash flow
$-5.34M
Avg volume
257,216
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$7.40M
- Net income-$4.85M
- Diluted EPS-0.02
- Free cash flow-$5.05M
- Net debt-$2.93M